Sulindac sodium
Based on 1 publication(s) in Google Scholar
Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer.
For research use only. We do not sell to patients.
- CAS No.: 63804-15-9
- Formula: C20H16FNaO3S
- Molecular Weight:378.39
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Sulindac sodium
More
Biological Activity
Sulindac (MK-231) (500 μM, 48 h) sodium is effective in preventing TGF-β1-induced EMT, as indicated by upregulation of the epithelial marker, E-cadherin, and downregulation of mesenchymal markers and transcription factors[1].
Sulindac sodium (500 μM, 48 h) can inhibit TGF-β1-enhanced migration and invasion of A549 cells[1].
Sulindac sodium (500 μM, 48 h) enhances the reversal of TGF-β1-induced EMT by sulindac (sodium) and SIRT1 upregulation promoted TGF-β1-induced EMT[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 cells
-
Concentration:500 μM
-
Incubation Time:48 h
-
Result:Inhibit transforming growth factor (TGF)-β1-induced epithelial-mesenchymal transition in A549 cells.
-
Cell Line:A549 cells
-
Concentration:500 μM
-
Incubation Time:48 h
-
Result:Reversed SIRT-1 expression by TGF-β1 and inhibited the TGF-β1-induced cadherin switch.
-
Cell Line:A549 cells
-
Concentration:500 μM
-
Incubation Time:48 h
-
Result:Inhibited migration, decreased resistance co-treatment with TGF-β1.
-
Cell Line:A549 cells
-
Concentration:500 μM
-
Incubation Time:40 h; 48 h
-
Result:Could effectively inhibit the TGF- β1-induced increase in invasion by lung cancer cells.
Sulindac sodium (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) can downregulate PD-L1 by blocking NF-κB signaling, which in turn led to a decrease in exosomal P[2].
Sulindac sodium (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) leads to increased availability of PD-L1 Ab by downregulating PD-L1 in combination therapy[2].
Sulindac sodium has not a systemic inhibitory effect on prostaglandin E2 (PGE2) in low-dose does[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CT26 syngeneic mouse tumor model[2]
-
Dosage:15 mg/kg; 7.5 mg/kg
-
Administration:15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)
-
Result:Downregulated PD-L1 through the blockade of NF-κB signaling and modulate the response of pMMR CRC to anti-PD-L1 immunotherapy.
-
Animal Model:CT26 syngeneic mouse tumor model[2]
-
Dosage:15 mg/kg; 7.5 mg/kg
-
Administration:15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)
-
Result:Downregulated PD-L1 through the blockade of NF-κB signaling and modulate the response of pMMR CRC to anti-PD-L1 immunotherapy.
Cound effectively inhibit PD-L1 with no significant systematic toxicity.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 63804-15-9
-
Molecular Weight 378.39
-
Formula C20H16FNaO3S
-
SMILES
O=C(CC(C1=C2C=CC(F)=C1)=C(/C2=C/C3=CC=C(C=C3)S(C)=O)C)O[Na]
-
Synonyms
MK-231 sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
bioRxiv
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG. [Abstract]2026 Apr 18:2026.04.17.719256. PMID: 42039650
Purity & Documentation
References
[1]. Byong-Ki Cha, et al. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget. 2016 Aug 30;7(35):57213-57227. [Content Brief]
[2]. Bin Yi, et al. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy. Mol Cancer Ther. 2021 Jul;20(7):1295-1304. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz